Did you know that seven out of every 1,000 people around the world suffer from epilepsy?
Based on statistics gathered by the World Health Organization, approximately 50 million of Planet Earth’s inhabitants struggle with some form of epilepsy and an additional 2.4 million are newly diagnosed with the debilitating disease on an annual basis.
Medical marijuana could be the answer, after numerous clinical trials have exposed how medical weed can relieve the symptoms of epilepsy, including seizures. In a revolutionary twist of events, on June 27, 2018, the Federal Drug Administration (FDA) officially approved a cannabis-derived drug that enables patients with rare forms of epilepsy to be treated with medical cannabis.
What is Epidiolex?
GW Pharmaceuticals is the British-based company that accomplished a historic milestone in medical cannabis on June 25, 2018. It was on this date that the company’s CBD medicine Epidiolex was given the thumbs-up by the FDA. The proprietary oral solution is purely plant-derived and it has been developed for the treatment of seizures in patients with Dravet and Lennox Gastaut syndromes. Once placed on the Drug Schedule by the Drug Enforcement Administration (DEA), Epidiolex can be distributed to the legal cannabis market.
Epidiolex has also been evaluated for its potential as a treatment for patients with infantile spasms and tuberous sclerosis. Ongoing evaluations will determine whether or not this non-psychoactive treatment (Epidiolex is THC-free) can be utilized as an additional form of therapy for adults who suffer from partial (focal) seizures. If this happens, the market for Epidiolex will expand further and provide investors with an incredible opportunity to reap the financial rewards of medical marijuana.
Why is CBD-rich medical marijuana suitable as an epilepsy treatment?
The non-psychoactive cannabinoid contained in Epidiolex may be derived from the same Cannabis sativa plant that THC (tetrahydrocannabinol) is derived from, but it is not a mind-altering substance. Safe and natural, this treatment is ideal for young patients with epilepsy since it is non-intoxicating. Patients who use medicinal cannabis can experience relief from epileptic seizures when their body’s natural endocannabinoid system (ECS) is triggered by cannabinoids, like CBD.
Investing in a Medical Cannabis Company that Specializes in Epilepsy Treatments
Currently, the cannabis industry is heavily focused on the potential of medical weed as an epilepsy treatment. Cases relating to young epilepsy sufferers, such as the case of Billy Caldwell, are helping to mold the medical cannabis industry in the U.S., Canada and now, the United Kingdom is getting on-board too.
This signifies a major change in opinion on the use of cannabis for pediatric patients and since the FDA has approved Epidiolex as a cannabis-derived epilepsy treatment, a new door has opened for other cannabinoid drug producers to market their medicinal products.
It’s exciting to think about the potential of cannabis to drastically improve the treatment of so many individuals suffering from debilitating health conditions – and how that could increase the profitability of cannabis companies specializing in medical cannabis.
Written by Lior Ishai